[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression-during-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression-during-pregnancy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100652477","treatment-with-repetitive-transcranial-magnetic-stimulation-in-peripartal-depression-100652477",false,"NCT07774559","Treatment With Repetitive Transcranial Magnetic Stimulation in Peripartal Depression","PPD and rTMS","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Currently pregnant or up to 12 months after childbirth at screening\n* Current depressive episode or clinically significant depressive symptoms consistent with peripartum depression, confirmed by clinical interview according to ICD-10 criteria\n* MADRS score of at least 7 at screening\n* Able to understand German or English\n* Able to provide written informed consent\n* Willing and able to attend study visits and complete rTMS procedures, EEG and ECG recordings, hair and sputum sampling, and study questionnaires\n* Stable antidepressant and\u002For psychotherapy treatment, or no current antidepressant medication and\u002For psychotherapy; participants should agree to maintain treatment stability during the study where clinically feasible\n* Previous rTMS treatment for depression is permitted\n\nExclusion Criteria:\n\n* Current or past seizure disorder, or previous rTMS-induced seizure\n* Primary psychotic disorder\n* Acute suicidality requiring a higher level of care\n* Contraindications to rTMS, including intracranial metallic implants; implanted neurostimulators; cochlear implants; vagus nerve stimulators; ocular implants; implanted cardiac electrodes or pacemakers; aneurysm coils or clips; ventriculo-peritoneal shunts; or other ferromagnetic or electronic implants in the head or neck\n* Clinically significant head injury within the previous 12 months or with relevant residual symptoms\n* Unstable or severe medical or obstetric complications that could make participation unsafe, such as preeclampsia or imminent preterm labour requiring intensive management\n* Severe substance use disorder that could interfere with safety or study assessments\n* Inability to follow study procedures, for example because of cognitive impairment\n* Frequent severe migraine, including chronic migraine with status migrainosus, if high-frequency rTMS is considered likely to worsen symptoms, unless the investigator and treating physician determine that participation is safe.","FEMALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn whether repetitive transcranial magnetic stimulation (rTMS) can reduce depressive symptoms in women who are pregnant or up to 12 months after childbirth and have peripartum depression. rTMS is a non-invasive treatment in which a device placed on the scalp delivers gentle magnetic pulses to a brain area involved in mood regulation. It does not involve medication or anaesthesia.\n\nThe main questions this study aims to answer are:\n\n* Does active rTMS reduce depressive symptoms more than sham rTMS?\n* What side effects occur during treatment, and how well is rTMS tolerated?\n* Are improvements in depressive symptoms still present one month after treatment?\n\nResearchers will compare active rTMS with sham rTMS, a treatment designed to feel and sound similar but not to provide effective brain stimulation. Neither participants nor the clinicians assessing depressive symptoms will know which treatment was assigned during the main study phase.\n\nUp to 60 women aged 18 years or older who are pregnant or up to 12 months after childbirth and have clinically relevant depressive symptoms may take part. Participants will:\n\n* Attend a screening and baseline visit, including questionnaires, EEG and ECG recordings, and collection of small hair and sputum samples to study stress-related hormone levels\n* Be assigned by chance to receive either active rTMS or sham rTMS\n* Attend 30 treatment sessions, scheduled flexibly over approximately 1.5 to 10 weeks to accommodate childcare, breastfeeding, fatigue, and medical appointments\n* Complete questionnaires about mood, wellbeing, quality of life, social support, and treatment expectations before and after treatment\n* Have safety and side effects checked before each treatment session\n* Complete a telephone follow-up assessment one month after treatment\n* Be asked to complete a short questionnaire about their child's development one year after treatment\n\nEach treatment visit lasts about 30 minutes, including preparation, treatment, and a short safety check. Infants may be brought to treatment visits when this can be done safely.\n\nrTMS is generally well tolerated. Possible temporary side effects include headache, scalp discomfort, facial muscle twitching during stimulation, dizziness, or tiredness. A seizure is a very rare but serious possible risk; therefore, people with epilepsy, certain implants, or other relevant risk factors cannot take part.\n\nParticipation is voluntary. Participants can pause or stop participation at any time without affecting their usual care. Personal data will be coded and handled confidentially. Women assigned to sham treatment will be offered active rTMS after the blinded study phase, if they wish. The results may help clarify whether rTMS is an effective non-medication treatment option for peripartum depression.",[26,27,28],"Depression During Pregnancy","Postpartum Depression (PPD)","Peripartum Depression",[30,31,32,33,34,35],"Peripartal depression","Postpartal depression","Antenatal depression","Repetitive transcranial magnetic stimulation","Transcranial magnetic stimulation","rTMS","NOT_YET_RECRUITING","2026-08-17",{"date":39,"type":40},"2026-08-19","ACTUAL",{"date":42,"type":20},"2026-09",{"date":44,"type":20},"2030-08-31",{"name":46,"class":47},"Psychiatric University Hospital, Zurich","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100566756","prevention-of-mother-to-child-transmission-pmtct-among-women-experiencing-depression-in-malawi-100566756","NCT06659315","Prevention of Mother-to-child Transmission (PMTCT) Among Women Experiencing Depression in Malawi","Addressing Perinatal Depression and PMTCT Adherence in Malawi: A Couple-Based Approach","Inclusion Criteria:\n\n* In a marriage or cohabitating union for at least 6 months.\n* One member of the couple is a woman in the second or third trimester of pregnancy who is living with HIV and screens positive for depression (\\>10 on the PHQ9).\n* Have revealed their HIV status to their partner if living with HIV\\>\n\nExclusion Criteria:\n\n* Fear their safety would be at risk.\n* Report incidents of severe intimate partner violence (IPV) in the past three months using the WHO IPV measure.","ALL",{"count":57,"type":20},180,[23],"Prevention of mother-to-child transmission (PMTCT) of HIV virtually eliminates transmission of HIV from mothers to their infants. Adherence to PMTCT (i.e., to antiretroviral therapy, infant prophylaxis, and exclusive breastfeeding) during pregnancy and the postpartum period is challenging, with evidence from sub-Saharan Africa (SSA) showing suboptimal adherence and persistent viremia among perinatal women. Perinatal depression (PD) is a major driver of women's poor adherence to PMTCT. Interventions that involve male partners to provide social and food\u002Feconomic support could be a promising approach for addressing PD and PMTCT, yet few interventions have intervened with couples to improve systems of support, communication, and other dyadic processes. The investigators propose to develop and test a couple-based approach to intervene on the mother's perinatal depressive symptoms and to strengthen the relationship and support system for partners to work together around depression to improve PMTCT adherence. The study will take place in antenatal and HIV care settings in Zomba, Malawi. The specific aims are: (1) to develop a couple-based intervention to target perinatal depression (PD) based on an evidence-based approach using problem-solving therapy (PST), augmented with content on couple communication and problem-solving skills; and (2) to assess the feasibility and acceptability (F\\&A) of the intervention via a pilot randomized controlled trial (RCT). Our short-term goal is the produce a couple-focused PST intervention that can be added to the global health toolkit for treating depression in perinatal women. Our long-term goal is to produce a high-impact and sustainable intervention leveraging the couple relationship that can be scaled-up to address depression, PMTCT adherence, and family health.",[61,62,26,63],"HIV Antiretroviral Therapy (ART) Adherence","Perinatal Mental Health","PMTCT",[65,66,67,63,68],"Perinatal depression","Couples","Problem-solving","ART adherence","RECRUITING","2026-03-26",{"date":72,"type":40},"2026-03-30",{"date":74,"type":40},"2025-11-11",{"date":76,"type":20},"2027-07-01",{"name":78,"class":47},"University of California, San Francisco",1]